Patient-friendly evidence guides
Peptide education built to resist the hype cycle.
Start with what was studied, in whom, with which exact substance, and what remains unknown. These guides explain approved medicines and investigational peptides at their actual evidence level.
The whole library
Six topics, compared on the same terms
“Peptide” is not an evidence grade. This matrix keeps human data, regulatory status, and the main uncertainty visible together.
| Guide | Human evidence | Regulatory snapshot | Principal uncertainty |
|---|---|---|---|
| Peptides 101 | Varies by product and use | Mixed status; evaluate the exact product and use | The word “peptide” alone tells you almost nothing about whether a particular product improves a meaningful health outcome, what risks it carries, or whether evidence from one version applies to another. |
| GLP-1s | Established for specific approved uses | FDA-approved products exist; unapproved versions are distinct | Trial averages cannot predict an individual's response, tolerability, adherence, or longer-term course. Evidence from an approved product also cannot resolve the identity, quality, sterility, or performance of an unapproved version. |
| BPC-157 | Limited human evidence | Not FDA-approved; reviewed in the 2026 503A compounding process | The central uncertainty is not whether laboratory findings are interesting; it is whether a defined BPC-157 product produces a meaningful net benefit in people. Human efficacy, pharmacokinetics for commonly promoted routes, immunogenicity, dose–response, product quality, and longer-term safety remain inadequately characterized. |
| KPV | No informative administered-human evidence identified | Not FDA-approved; reviewed in the 2026 503A compounding process | The largest evidence gap is direct: no informative human administration data were identified. Exposure, clinical outcomes, pharmacokinetics, adverse effects, immunogenicity, interactions, and longer-term risks remain undetermined for people. |
| TB-500 | No informative administered-human evidence identified | Not FDA-approved; reviewed in the 2026 503A compounding process | The central problem is evidence identity: papers about thymosin beta-4, an unacetylated LKKTETQ fragment, cells, or animals are repeatedly treated as though they studied administered human TB-500. They did not resolve human efficacy, exposure, immunogenicity, or longer-term safety for a defined TB-500 product. |
| MOTS-c | No informative administered-human evidence identified | Not FDA-approved; reviewed in the 2026 503A compounding process | The unresolved question is whether an administered, well-characterized MOTS-c product can produce a clinically meaningful net benefit in people. Endogenous measurements, cells, and mouse treatment experiments do not establish human exposure, outcomes, safety, or longevity effects. |
Read deeply
The guide library
Peptides 101
A plain-language framework for separating peptide biology, approved medicines, compounding, and early research—without turning scientific interest into a treatment claim.
- Human evidence
- Varies by product and use
- Status
- Mixed status; evaluate the exact product and use
GLP-1s
A product-specific review of approved uses, landmark human trials, known risks, and the line between FDA-approved medicines and compounded or otherwise unapproved versions.
- Human evidence
- Established for specific approved uses
- Status
- FDA-approved products exist; unapproved versions are distinct
BPC-157
A careful review of BPC-157 identity, the small human evidence base, preclinical findings, unresolved safety questions, and the 2026 FDA compounding review.
- Human evidence
- Limited human evidence
- Status
- Not FDA-approved; reviewed in the 2026 503A compounding process
KPV
What cell and mouse studies suggest, why they do not demonstrate patient benefit, and what FDA found when it reviewed KPV-related substances in 2026.
- Human evidence
- No informative administered-human evidence identified
- Status
- Not FDA-approved; reviewed in the 2026 503A compounding process
TB-500
A substance-specific review of the acetylated fragment called TB-500, the evidence that is often misattributed to it, and the unresolved human and product-quality questions.
- Human evidence
- No informative administered-human evidence identified
- Status
- Not FDA-approved; reviewed in the 2026 503A compounding process
MOTS-c
A close look at mitochondrial peptide biology, the human exercise observation, intervention results in cells and mice, and the missing evidence for administered MOTS-c in people.
- Human evidence
- No informative administered-human evidence identified
- Status
- Not FDA-approved; reviewed in the 2026 503A compounding process
How to read the research
The evidence ladder
Each rung answers a different question. Evidence lower on the ladder can be important without establishing a treatment benefit in people.
- Human outcomes
Controlled human studies that measure how people feel, function, develop disease, or experience harm provide the most direct treatment evidence.
- Human biomarkers and pharmacology
Human exposure, laboratory markers, or physiologic associations can explain what happens in the body without proving a meaningful clinical benefit.
- Animal research
Animal models can test mechanisms and early safety questions, but species, model, exposure, and endpoints limit direct translation to patients.
- Cell and biochemical research
Experiments in cells, tissues, or chemical systems can generate hypotheses; they do not show that a finished product improves a human outcome.
- Unsupported hypothesis or marketing claim
A proposed benefit without direct supporting evidence should be presented as an untested claim, not as a low-grade version of a proven result.
Reading the 2026 FDA record
Discussion is not approval
The July 2026 meeting concerned a statutory compounding pathway. The steps below keep that process separate from FDA drug approval.
- A substance is nominated
A nomination asks FDA to consider whether a bulk drug substance may qualify for a statutory compounding list. It is not a drug-approval application.
- FDA staff assess the record
FDA examines characterization, historical use, effectiveness, and safety in the context of the nomination and prepares a public briefing memorandum.
- PCAC gives nonbinding advice
The Pharmacy Compounding Advisory Committee discusses the questions and advises FDA. Its recommendation is nonbinding and is not FDA approval.
- FDA considers final agency action
FDA considers the committee input and completes its reviews before any final agency action. A meeting or staff position alone is not that final step.
Education, not individualized medical advice
These guides do not diagnose, prescribe, recommend a product, or replace a licensed clinician who knows a person's history. They are designed to make uncertainty and source quality easier to see.